ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices.

Nordic Capital Funds VI and VII acquired a majority shareholding in ConvaTec in August 2008. Since then, the company has grown to become one of the leading medical technology companies globally, with a strong focus on structurally growing chronic care markets and sales to patients and healthcare professionals in more than 100 countries.

During Nordic Capital's ownership, the company has benefited from ongoing operational improvements, organic growth and complementary acquisitions. Key acquisitions include Unomedical, a leading manufacturer of single-use medical devices based in Copenhagen, which was also backed by Nordic Capital; and 180 Medical, through which ConvaTec distributes intermittent urological catheters directly to patients in the United States.

The company was listed on the London Stock Exchange in October 2016. Together, Nordic Capital Funds VI and VII, owns approximately 7.3% of the shares (as per June 2017).

Key Information

Revenues Icon

Revenues 2017*

EUR 1470 million

Employees Icon



Ownership Icon


Nordic Capital Fund VI and Fund VII, controlling shareholding

Investment Icon

Investment date


* Annual report